May 3 (Reuters) - Teva Pharmaceutical Industries Ltd :
* TEVA PHARM CEO TO REUTERS: “CLOSE RACE” WITH ELI LILLY FOR SECOND MIGRAINE DRUG LAUNCH
* TEVA PHARM CEO TO REUTERS: MIGRAINE DRUG TO BE PRICED AT ABOUT $10,000 A YEAR, SIMILAR TO COMPETITORS
* TEVA CEO TO REUTERS: WE ARE SEEING SOME STABILIZATION IN U.S. GENERIC DRUG PRICES
* TEVA CEO TO REUTERS: WORKING WITH CUSTOMERS TO ENSURE PATIENTS NOT AFFECTED AS IT PHASES OUT SOME GENERIC DRUG PRODUCTS
* TEVA CEO TO REUTERS: U.S. BIOSIMILAR MARKET IN EARLY STAGES SO TEVA WILL BE ABLE TO CATCH UP Further company coverage: (Reporting by Steven Scheer and Tova Cohen)